Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study (original) (raw)

Cost-effectiveness of tenofovir in the treatment of patients with chronic hepatitis B: data from literature

Farmeconomia. Health economics and therapeutic pathways, 2014

Chronic hepatitis B (CHB) is a complex disease with significant social impact both on the patients’ quality of life of and the economic resources involved. Its chronicity affects considerably not only the clinical management of the disease (for the need for drugs with proven long-term safety and low rate of resistance), but also the economic impact (for the high costs of treatment, the management of complications, and the constant monitoring of therapy).Since, as is well known, the main problem of modern health care systems is the general scarcity of available resources in the face of growing demand for health, the issue of economic evaluation of therapies for the treatment of chronic hepatitis B has been addressed in numerous national and international studies. In fact, clinicians find a strong support for the choice of the most suitable therapeutic pathway in the major scientific societies’ guidelines (European Association for the Study of The Liver – EASL, American Association fo...

[The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Health. Italian Society of Pediatrics. Italian Federation of Pediatric Physicians. Italian Federation of General Medical Physicians. Arezzo Service of Le

Epidemiologia e prevenzione, 2014

Paolo Bonanni SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Chiara Azzari SIP, Società italiana di pediatria Paolo Castiglia SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Giampietro Chiamenti FIMP, Federazione italiana medici pediatri Giorgio Conforti FIMP, Federazione italiana medici pediatri Michele Conversano SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Giovanni Corsello SIP, Società italiana di pediatria Giuseppe Ferrera SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Antonio Ferro SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Giancarlo Icardi SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Pasquale Giuseppe Macrì ASL Arezzo, Servizio di medicina legale Tommaso Maio FIMG, Federazione italiana medici di medicina generale Walter Ricciardi SItI, Società italiana di igiene, medicina preventiva e sanità pubblica Rocco Russo SIP, Soci...

[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]

Clinical Management Issues, 2015

BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature, there are a few studies comparing entecavir and tenofovir in the treatment of CHBV. Thus, we describe the results of our experience in managing CHBV patients with tenofovir vs. entecavir.MATERIALS AND METHODS: We have retrospectively evaluated, from 2007 to date, 20 CHBV patients treated with entecavir and tenofovir. All the patients underwent basal and periodical clinical follow-up, blood tests, virological tests, Fibroscan® test or liver biopsy and also upper abdominal ultrasound examination. Study endpoints were: viral replication inhibition, viral antigens seroconversion and transaminases normalization. Drug-associated side effects were also registered.RESULTS: After 12 weeks of thera...

Vaccines against SARS CoV 2 and the vaccination campaign in Italy

The Journal of AMD, 2021

The SARS COV 2 pandemic has created an unprecedented need to manufacture and distribute a safe and effective vaccine to immunize an exceptionally large number of individuals planning diversified vaccination approaches quickly. A few weeks have passed since the sequencing of the viral genome for the design of the first vaccines and a few months for the implementation of the efficacy and safety studies. The article analyzes the types of vaccines available by examining their characteristics, efficacy and safety, also examining some debated issues such as the thrombotic risk of viral vector vaccines. The second part deals with the issue of the vaccination campaign in our country. KEY WORDS vaccination; COVID-19; spike protein; efficacy; safety.